Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15906056 | 0.86 | MAPK14 (0.47) | MAPK14JAK2NTRK1CA2HTR7 | |
| SCHEMBL18812550 | 0.84 | MAPK14 (0.46) | MAPK14JAK2NTRK1CA2 | |
| SCHEMBL12943793 | 0.81 | MAPK14 (0.44) | MAPK14JAK2NTRK1CA2HTR7 | |
| SCHEMBL18812376 | 0.81 | RBP4 (0.46) | MAPK14JAK2NTRK1CA2HTR7 | |
| SCHEMBL13286431 | 0.80 | MAPK14 (0.45) | MAPK14JAK2NTRK1CA2HTR7 | |
| SCHEMBL9652424 | 0.79 | HTT (0.39) | CA2 | |
| SCHEMBL13463048 | 0.78 | MAPK14 (0.52) | MAPK14CA2 | |
| SCHEMBL9774733 | 0.77 | MAPK14 (0.53) | MAPK14CA2DRD4 | |
| SCHEMBL9774729 | 0.77 | MAPK14 (0.53) | MAPK14CA2DRD4 | |
| SCHEMBL18791256 | 0.76 | JAK2 (0.58) | MAPK14JAK2NTRK1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682979-B2 | Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150031667-A1 | Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA, INC. | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031667-A1 | Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors | TXK, FRK, LTK | MAPK14 263/4885JAK2 124/4885NTRK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.